Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Virological and antigenic characteristics of SARS-CoV-2 variants LF. 7.2. 1, NP. 1, and LP. 8.1
Recently, XEC and KP. 3.1. 1 have surpassed KP. 3 to become the globally dominant
lineages of SARS-CoV-2 due to the unique N-terminal domain (NTD) mutations, including …
lineages of SARS-CoV-2 due to the unique N-terminal domain (NTD) mutations, including …
Immune Evasion, Cell-Cell Fusion, and Spike Stability of the SARS-CoV-2 XEC Variant: Role of Glycosylation Mutations at the N-terminal Domain
SARS-CoV-2 continues to evolve, producing new variants that drive global COVID-19
surges. XEC, a recombinant of KS. 1.1 and KP. 3.3, contains T22N and F59S mutations in …
surges. XEC, a recombinant of KS. 1.1 and KP. 3.3, contains T22N and F59S mutations in …
[HTML][HTML] Mutational Scanning and Binding Free Energy Computations of the SARS-CoV-2 Spike Complexes with Distinct Groups of Neutralizing Antibodies: Energetic …
The rapid evolution of SARS-CoV-2 has led to the emergence of variants with increased
immune evasion capabilities, posing significant challenges to antibody-based therapeutics …
immune evasion capabilities, posing significant challenges to antibody-based therapeutics …
[HTML][HTML] Quantitative Characterization and Prediction of the Binding Determinants and Immune Escape Hotspots for Groups of Broadly Neutralizing Antibodies Against …
A growing body of experimental and computational studies suggests that the cross-
neutralization antibody activity against Omicron variants may be driven by the balance and …
neutralization antibody activity against Omicron variants may be driven by the balance and …
The KP. 2-adapted COVID-19 vaccine improves neutralising activity against the XEC variant
The rapid spread and emergence of immune-evasive SARS-CoV-2 variants has led to a
2024 update of the COVID-19 vaccine. These variants include BA. 2.86-lineage variants …
2024 update of the COVID-19 vaccine. These variants include BA. 2.86-lineage variants …
The potential impact of the spreading of highly transmissible Omicron variant XBB. 1.5 and JN. 1 on the evolution of SARS-CoV-2
In spite of three-year pandemic time caused by Covid-19, the trend and impact of the
evolution of SARS-CoV-2 remain unclear. For newly emerging variants, it is still hard to …
evolution of SARS-CoV-2 remain unclear. For newly emerging variants, it is still hard to …
[HTML][HTML] Immune Response to SARS-CoV-2 XBB. 1.5 and JN. 1 Variants Following XBB. 1.5 Booster Vaccination in Liver Transplant Recipients
P von der Schulenburg, GMN Behrens, M Hoffmann… - Viruses, 2024 - mdpi.com
Background/Objectives: The efficacy of monovalent BNT162b2 Omicron XBB. 1.5 booster
vaccination in liver transplant recipients (LTRs) has yet to be described, particularly …
vaccination in liver transplant recipients (LTRs) has yet to be described, particularly …
Increased preference for lysine over arginine in spike proteins of SARS-CoV-2 BA. 2.86 variant and its daughter lineages
The COVID-19 pandemic offered an unprecedented glimpse into the evolution of its
causative virus, SARS-CoV-2. It has been estimated that since its outbreak in late 2019, the …
causative virus, SARS-CoV-2. It has been estimated that since its outbreak in late 2019, the …
Low levels of neutralizing antibodies against SARS-CoV-2 KP. 3.1. 1 and XEC in serum from seniors in May 2024
New immune evasive variants of SARS-CoV-2 may increase infections and hospitalizations
in risk groups, such as the elderly. In this study we evaluated neutralizing antibodies against …
in risk groups, such as the elderly. In this study we evaluated neutralizing antibodies against …
[PDF][PDF] Article Not peer-reviewed version
M Alshahrani, V Parikh, B Foley, N Raisinghani… - 2025 - preprints.org
The rapid evolution of SARS-CoV-2 has led to the emergence of variants with increased
immune evasion capabilities, posing significant challenges to antibody-based therapeutics …
immune evasion capabilities, posing significant challenges to antibody-based therapeutics …